Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tacrolimus
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Recipient : Massachusetts General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 30, 2024
Lead Product(s) : Tacrolimus
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Recipient : Massachusetts General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : T-Guard
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Xenikos B.V
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : T-Guard (ricin toxin A conjugated mAB) is designed to reset the body's immune system in life-threatening T cell‒mediated conditions, potentially including prevention of transplant-related rejection, treatment of acute solid-organ rejection, and severe ...
Product Name : T-Guard
Product Type : Antibody
Upfront Cash : Inapplicable
June 28, 2022
Lead Product(s) : T-Guard
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Xenikos B.V
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FR104
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : Asahi Kasei Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VEL-101 (FR104) is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 18, 2022
Lead Product(s) : FR104
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : Asahi Kasei Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FR104
Therapeutic Area : Immunology
Study Phase : Phase I
Sponsor : OSE Immunotherapeutics SA
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VEL-101/FR104 is a novel investigational maintenance immunosuppressive agent being developed for prevention of acute rejection in kidney transplant recipients.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
May 18, 2022
Lead Product(s) : FR104
Therapeutic Area : Immunology
Highest Development Status : Phase I
Sponsor : OSE Immunotherapeutics SA
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 23, 2022
Lead Product(s) : VEL-101
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
February 14, 2022
Lead Product(s) : VEL-101
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tacrolimus
Therapeutic Area : Nephrology
Study Phase : Phase IV
Recipient : Loyola University
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
June 08, 2021
Lead Product(s) : Tacrolimus
Therapeutic Area : Nephrology
Highest Development Status : Phase IV
Recipient : Loyola University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FR104
Therapeutic Area : Immunology
Study Phase : Phase I
Recipient : OSE Immunotherapeutics SA
Deal Size : $393.6 million
Deal Type : Collaboration
Details : The collaboration grants Veloxis worldwide rights to develop, manufacture and commercialize FR104, a CD28 antagonist monoclonal antibody fragment, for all transplant indications. OSE Immunotherapeutics retains all rights to develop FR104 in autoimmune di...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : $8.5 million
April 26, 2021
Lead Product(s) : FR104
Therapeutic Area : Immunology
Highest Development Status : Phase I
Recipient : OSE Immunotherapeutics SA
Deal Size : $393.6 million
Deal Type : Collaboration
Lead Product(s) : Tacrolimus
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Recipient : Vanderbilt University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Cognitive Outcomes in Stable Renal Transplant Patients Switched FromTacrolimus to Envarsus XRâ„¢
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 09, 2021
Lead Product(s) : Tacrolimus
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Recipient : Vanderbilt University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tacrolimus
Therapeutic Area : Immunology
Study Phase : Phase IV
Recipient : University of Southern California
Deal Size : Inapplicable
Deal Type : Inapplicable
Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
February 26, 2021
Lead Product(s) : Tacrolimus
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Recipient : University of Southern California
Deal Size : Inapplicable
Deal Type : Inapplicable